Vitiligo, Generalized

3

Review clinical trials related to Vitiligo, Generalized. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

This study aims to compare the efficacy and safety of PUVA versus Tofacitinib in the treatment of generalized vitiligo. Given the high prevalence of vitiligo in Pakistan and the significant psychosocial impact on patients, particularly in Peshawar, this study will provide valuable insights into optimal treatment strategies.

Participants needed: 64
Trial details
Phase: Early Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Hayat Abad Medical Complex, PeshawarUpdated: Jan 30, 2026Locations: 1
Eligibility criteria

• Patients of either gender aged 18-60 years, diagnosed with generalized vitilig... [+1]

Patients with a history of photosensitivity or allergies to Psoralen or Tofaciti... [+1]

Status: Recruiting

Vitiligo, New Treatment and Serum s100B

vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem. Multiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors

Participants needed: 50
Trial details
Phase: Phase 2, Phase 3Age: 10-75Biological sex: AllType: InterventionalSponsor: South Valley UniversityUpdated: Jan 10, 2025Locations: 1
Eligibility criteria

active generalized vitiligo patients with body surface area involved >5% excludi... [+1]

acrofacial, acral, segmental or mucosal vitiligo [+5]

Status: Not yet recruiting

Gasdermin D Expression in Generalized Vitiligo Patients After Narrow-band Ultraviolet B Therapy

The aim of this study is to: 1. Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls. 2. Evaluation expression of tissue Gasdermin D using immunehistochemstry techniques in patients with generalized vitiligo after narrow band ultraviolet B therapy. 3. Determine whether there is a relationship between Gasdermin D levels and disease duration and involved body surface area (VISA) in vitiligo patients.

Participants needed: 40
Trial details
Age: 10-75Biological sex: AllType: InterventionalSponsor: South Valley UniversityUpdated: Aug 9, 2024
Eligibility criteria

Patients with stable vitiligo of 6 months duration, [+1]

pregnancy, [+4]